Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Dermacyd PH_DETINLYN Sweet Flower · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Dermacyd PH\_DETINLYN Sweet Flower (Lactic Acid) |
| Name | Type | Description |
|---|---|---|
| Dermacyd PH_DETINLYN Sweet Flower (Lactic Acid) | DRUG | - |
Inclusion Criteria: * Integral skin test in the region, * Use of cosmetic product of the same category Exclusion Criteria: * Lactation or gestational risk or gestation * Use of Anti-inflammatory, immunosuppression or anti-histaminic drugs * Atopic antecedent or allergic to cosmetic product * Acti...
Dermacyd PH_DETINLYN Sweet Flower is a small molecule product developed for hygiene purposes. It is intended for use in maintaining hygiene, and the clinical trial for this product enrolled female participants aged 10 years and older. The product is currently in Phase 3 clinical development.
Dermacyd PH_DETINLYN Sweet Flower is developed by Sanofi, a company listed on the stock exchange under the ticker SNY. The product is being investigated for hygiene applications and is currently in Phase 3 clinical development.
Dermacyd PH_DETINLYN Sweet Flower is in Phase 3 clinical development. It is an investigational product for hygiene use and has not been approved by regulatory authorities. The product is being studied in a completed Phase 3 trial.
Dermacyd PH_DETINLYN Sweet Flower has one completed clinical trial, identified as NCT00785148. This Phase 3 trial, titled 'Dermacyd PH_DETINLYN Sweet Flower (Lactic Acid) - Safety', enrolled 31 participants in Brazil. The study was uncontrolled and involved healthy female volunteers.
Dermacyd PH_DETINLYN Sweet Flower is not FDA approved. It is an investigational product currently in Phase 3 clinical development for hygiene use. The product has completed a clinical trial, but approval status has not been established.